Please login to the form below

Not currently logged in
Email:
Password:

Zentiva

This page shows the latest Zentiva news and features for those working in and with pharma, biotech and healthcare.

Sanofi warns of difficult few months as diabetes sales slump

Sanofi warns of difficult few months as diabetes sales slump

said that the last few months have included the pipeline-building acquisitions of Bioverativ and Ablynx and the sale of its Zentiva generics business to a private equity group.

Latest news

  • Sanofi appoints ex-Roche Reed as new R&D head Sanofi appoints ex-Roche Reed as new R&D head

    Brandicourt has also demonstrated his commitment to pursuing the core pharma business at Sanofi by selling off its Zentiva generics business for 1.9bn ($2.4bn).

  • Sanofi sells European generics to Advent for $2.4bn Sanofi sells European generics to Advent for $2.4bn

    Sanofi has been looking to divest the Zentiva generics unit since 2016 as part of restructuring the business under chief executive Olivier Brandicourt, who said: “Transferring this business to Advent is ... Sanofi bought the foundations of its European

  • Ten new medicines recommended in Europe Ten new medicines recommended in Europe

    Duloxetine Zentiva (duloxetine) - a copycat of Lilly's Cymbalta - for the treatment of major depressive disorder, diabetic peripheral neuropathic pain and generalised anxiety disorder, also saw a nod from the EMA.

  • Three cancer immunotherapies amongst new CHMP approvals Three cancer immunotherapies amongst new CHMP approvals

    Finally, two generic medicines gained positive opinions: Bortezomib Accord (bortezomib) for the treatment of multiple myeloma and mantle cell lymphoma and Pregabalin Zentiva (pregabalin) for the treatment of epilepsy and generalised

  • Orphan drugs in latest CHMP recommendations Orphan drugs in latest CHMP recommendations

    Completing the positive opinions were two new informed consent applications: Sevelamer carbonate Zentiva (sevelamer) from Genzyme for the control of hyperphosphataemia in adults receiving haemodialysis or peritoneal dialysis and Rasagiline

More from news
Approximately 1 fully matching, plus 16 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics